Human antigen R: Exploring its inflammatory response impact and significance in cardiometabolic disorders.
HuR
RNA-binding proteins (RBPs)
abnormal vision Drosophila-like 1 (ELAVL1)
cardiometabolic disease
inflammation
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
revised:
30
01
2024
received:
13
11
2023
accepted:
14
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
RNA-binding proteins (RBPs) play a crucial role in the regulation of posttranscriptional RNA networks, which can undergo dysregulation in many pathological conditions. Human antigen R (HuR) is a highly researched RBP that plays a crucial role as a posttranscriptional regulator. HuR plays a crucial role in the amplification of inflammatory signals by stabilizing the messenger RNA of diverse inflammatory mediators and key molecular players. The noteworthy correlations between HuR and its target molecules, coupled with the remarkable impacts reported on the pathogenesis and advancement of multiple diseases, position HuR as a promising candidate for therapeutic intervention in diverse inflammatory conditions. This review article examines the significance of HuR as a member of the RBP family, its regulatory mechanisms, and its implications in the pathophysiology of inflammation and cardiometabolic illnesses. Our objective is to illuminate potential directions for future research and drug development by conducting a comprehensive analysis of the existing body of research on HuR.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Qatar National Research Fund
ID : NPRP14S-0406-210150
Organisme : Qatar National Research Fund
ID : NPRP13S-0213-200352
Organisme : Qatar National Research Fund
ID : GSRA10-L-1-0612-23121
Organisme : Qatar University
Organisme : Qatar National Library
Informations de copyright
© 2024 The Authors. Journal of Cellular Physiology published by Wiley Periodicals LLC.
Références
Ahmed, R., Muralidharan, R., Srivastava, A., Johnston, S. E., Zhao, Y. D., Ekmekcioglu, S., Munshi, A., & Ramesh, R. (2021). Molecular targeting of HuR oncoprotein suppresses MITF and induces apoptosis in melanoma cells. Cancers, 13(2), 166. https://doi.org/10.3390/cancers13020166
Al-Ahmadi, W., Al-Ghamdi, M., Al-Haj, L., Al-Saif, M., & Khabar, K. S. A. (2009). Alternative polyadenylation variants of the RNA binding protein, HuR: Abundance, role of AU-rich elements and auto-regulation. Nucleic Acids Research, 37(11), 3612-3624. https://doi.org/10.1093/nar/gkp223
Amadio, M., Bucolo, C., Drago, F., Govoni, S., & Pascale, A. (2009). A new potential pharmacological target in diabetic retinopathy: The HuR pathway. Acta Ophthalmologica, 87(s244). https://doi.org/10.1111/j.1755-3768.2009.219.x
Amadio, M., Bucolo, C., Leggio, G. M., Drago, F., Govoni, S., & Pascale, A. (2010). The PKCβ/HuR/VEGF pathway in diabetic retinopathy. Biochemical Pharmacology, 80(8), 1230-1237. https://doi.org/10.1016/j.bcp.2010.06.033
Amadio, M., Pascale, A., Cupri, S., Pignatello, R., Osera, C., D□Agata, V., D□Amico, A. G., Leggio, G. M., Ruozi, B., Govoni, S., Drago, F., & Bucolo, C. (2016). Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacological Research, 111, 713-720. https://doi.org/10.1016/j.phrs.2016.07.042
Apte, R. S., Chen, D. S., & Ferrara, N. (2019). VEGF in signaling and disease: Beyond discovery and development. Cell, 176(6), 1248-1264. https://doi.org/10.1016/j.cell.2019.01.021
Atasoy, U., Curry, S. L., López de Silanes, I., Shyu, A.-B., Casolaro, V., Gorospe, M., & Stellato, C. (2003). Regulation of eotaxin gene expression by TNF-α and IL-4 through mRNA stabilization: Involvement of the RNA-binding protein HuR. The Journal of Immunology, 171(8), 4369-4378. https://doi.org/10.4049/jimmunol.171.8.4369
Blanco, F. F., Preet, R., Aguado, A., Vishwakarma, V., Stevens, L. E., Vyas, A., Padhye, S., Xu, L., Weir, S. J., Anant, S., Meisner-Kober, N., Brody, J. R., & Dixon, D. A. (2016). Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget, 7(45), 74043-74058. https://doi.org/10.18632/oncotarget.12189
Bradley, J. (2008). TNF-mediated inflammatory disease. The Journal of Pathology, 214(2), 149-160. https://doi.org/10.1002/path.2287
Brennan, C. M., Gallouzi, I.-E., & Steitz, J. A. (2000). Protein ligands to HuR modulate its interaction with target mRNAs in vivo. The Journal of Cell Biology, 151(1), 1-14.
Chang, S.-H., Lu, Y.-C., Li, X., Hsieh, W.-Y., Xiong, Y., Ghosh, M., Evans, T., Elemento, O., & Hla, T. (2013). Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis. Journal of Biological Chemistry, 288(7), 4908-4921. https://doi.org/10.1074/jbc.M112.423871
Chen, C.-Y., Gherzi, R., Ong, S.-E., Chan, E. L., Raijmakers, R., Pruijn, G. J. M., Stoecklin, G., Moroni, C., Mann, M., & Karin, M. (2001). AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell, 107(4), 451-464. https://doi.org/10.1016/S0092-8674(01)00578-5
Cheng, M., Yang, L., Fan, M., An, S., & Li, J. (2019). Proatherogenic stimuli induce HuR in atherosclerosis through MAPK/ErK pathway. American Journal of Translational Research, 11(4), 2317-2327.
Coller, J., & Parker, R. (2005). General translational repression by activators of mRNA decapping. Cell, 122(6), 875-886. https://doi.org/10.1016/j.cell.2005.07.012
Cookson, M. R. (2017). RNA-binding proteins implicated in neurodegenerative diseases. Wiley Interdisciplinary Reviews: RNA, 8(1), e1397. https://doi.org/10.1002/wrna.1397
Corley, M., Burns, M. C., & Yeo, G. W. (2020). How RNA-binding proteins interact with RNA: Molecules and mechanisms. Molecular Cell, 78(1), 9-29. https://doi.org/10.1016/j.molcel.2020.03.011
Dai, W., Zhang, G., & Makeyev, E. V. (2012). RNA-binding protein HuR autoregulates its expression by promoting alternative polyadenylation site usage. Nucleic Acids Research, 40(2), 787-800. https://doi.org/10.1093/nar/gkr783
Denkert, C., Koch, I., von Keyserlingk, N., Noske, A., Niesporek, S., Dietel, M., & Weichert, W. (2006). Expression of the ELAV-like protein HuR in human colon cancer: Association with tumor stage and cyclooxygenase-2. Modern Pathology, 19(9), 1261-1269. https://doi.org/10.1038/modpathol.3800645
Dery, K. J., Nakamura, K., Kadono, K., Hirao, H., Kageyama, S., Ito, T., Kojima, H., Kaldas, F. M., Busuttil, R. W., & Kupiec-Weglinski, J. W. (2020). Human antigen R (HuR): A regulator of heme oxygenase-1 cytoprotection in mouse and human liver transplant injury. Hepatology, 72(3), 1056-1072. https://doi.org/10.1002/hep.31093
Diaz-Muñoz, M. D., Bell, S. E., Fairfax, K., Monzon-Casanova, E., Cunningham, A. F., Gonzalez-Porta, M., Andrews, S. R., Bunik, V. I., Zarnack, K., Curk, T., Heggermont, W. A., Heymans, S., Gibson, G. E., Kontoyiannis, D. L., Ule, J., & Turner, M. (2015). The RNA-binding protein HuR is essential for the B cell antibody response. Nature Immunology, 16(4), 415-425. https://doi.org/10.1038/ni.3115
Dixon, D. A., Tolley, N. D., King, P. H., Nabors, L. B., McIntyre, T. M., Zimmerman, G. A., & Prescott, S. M. (2001). Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. Journal of Clinical Investigation, 108(11), 1657-1665. https://doi.org/10.1172/JCI12973
Erkinheimo, T.-L., Lassus, H., Sivula, A., Sengupta, S., Furneaux, H., Hla, T., Haglund, C., Butzow, R., & Ristimäki, A. (2003). Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Research, 63(22), 7591-7594.
Evans, C. H. (1995). Nitric oxide: What role does it play in inflammation and tissue destruction? Agents and Actions Supplements, 47, 107-116. https://doi.org/10.1007/978-3-0348-7343-7_9
Fan, X. C., & Steitz, J. A. (1998). HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proceedings of the National Academy of Sciences, 95(26), 15293-15298.
Fernández-Hernando, C., Ramírez, C. M., Goedeke, L., & Suárez, Y. (2013). MicroRNAs in metabolic disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(2), 178-185. https://doi.org/10.1161/ATVBAHA.112.300144
Fu, X., Zhai, S., & Yuan, J. (2018). Endothelial HuR deletion reduces the expression of proatherogenic molecules and attenuates atherosclerosis. International Immunopharmacology, 65, 248-255. https://doi.org/10.1016/j.intimp.2018.09.023
Gerdts, E., & Regitz-Zagrosek, V. (2019). Sex differences in cardiometabolic disorders. Nature Medicine, 25(11), 1657-1666. https://doi.org/10.1038/s41591-019-0643-8
Good, P. J. (1995). A conserved family of elav-like genes in vertebrates. Proceedings of the National Academy of Sciences, 92(10), 4557-4561.
Govindappa, P. K., Patil, M., Garikipati, V. N. S., Verma, S. K., Saheera, S., Narasimhan, G., Zhu, W., Kishore, R., Zhang, J., & Krishnamurthy, P. (2020). Targeting exosome-associated human antigen R attenuates fibrosis and inflammation in diabetic heart. The FASEB Journal, 34(2), 2238-2251. https://doi.org/10.1096/fj.201901995R
Govindaraju, S., & Lee, B. S. (2013). Adaptive and maladaptive expression of the mRNA regulatory protein HuR. World Journal of Biological Chemistry, 4(4), 111-118. https://doi.org/10.4331/wjbc.v4.i4.111
Green, L. C., Anthony, S. R., Slone, S., Lanzillotta, L., Nieman, M. L., Wu, X., Robbins, N., Jones, S. M., Roy, S., Owens, A. P., Aube, J., Xu, L., Lorenz, J. N., Blaxall, B. C., Rubinstein, J., Benoit, J. B., & Tranter, M. (2019). Human antigen R as a therapeutic target in pathological cardiac hypertrophy. JCI Insight, 4(4), e121541. https://doi.org/10.1172/jci.insight.121541
Guo, J., Lv, J., Chang, S., Chen, Z., Lu, W., Xu, C., Liu, M., & Pang, X. (2016). Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget, 7(29), 45249-45262. https://doi.org/10.18632/oncotarget.9932
Guo, S., Zhang, M., & Huang, Y. (2024). Three ‘E’ challenges for siRNA drug development. Trends in Molecular Medicine, 30(1), 13-24. https://doi.org/10.1016/j.molmed.2023.10.005
Harvey, R. F., Smith, T. S., Mulroney, T., Queiroz, R. M. L., Pizzinga, M., Dezi, V., Villenueva, E., Ramakrishna, M., Lilley, K. S., & Willis, A. E. (2018). Trans-acting translational regulatory RNA binding proteins. WIREs RNA, 9(3), e1465. https://doi.org/10.1002/wrna.1465
Hashemi Goradel, N., Najafi, M., Salehi, E., Farhood, B., & Mortezaee, K. (2019). Cyclooxygenase-2 in cancer: A review. Journal of Cellular Physiology, 234(5), 5683-5699. https://doi.org/10.1002/jcp.27411
Hashimoto, S., & Kishimoto, T. (2022). Roles of RNA-binding proteins in immune diseases and cancer. Seminars in Cancer Biology, 86, 310-324. https://doi.org/10.1016/j.semcancer.2022.03.017
Hentze, M. W., Castello, A., Schwarzl, T., & Preiss, T. (2018). A brave new world of RNA-binding proteins. Nature Reviews Molecular Cell Biology, 19(5), 327-341. https://doi.org/10.1038/nrm.2017.130
Hinman, M. N., & Lou, H. (2008). Diverse molecular functions of Hu proteins. Cellular and Molecular Life Sciences, 65(20), 3168-3181. https://doi.org/10.1007/s00018-008-8252-6
Huang, X.-M., Liu, Q., Xu, Z.-Y., Yang, X.-H., Xiao, F., Ouyang, P.-W., Yi, W.-Z., zhao, N., Meng, J., Cui, Y.-H., & Pan, H.-W. (2023). Down-regulation of HuR inhibits pathological angiogenesis in oxygen-induced retinopathy. Experimental Eye Research, 227, 109378. https://doi.org/10.1016/j.exer.2022.109378
Kapral, T. H., Farnhammer, F., Zhao, W., Lu, Z. J., & Zagrovic, B. (2022). Widespread autogenous mRNA-protein interactions detected by CLIP-seq. Nucleic Acids Research, 50(17), 9984-9999. https://doi.org/10.1093/nar/gkac756
Kawasaki, T., & Kawai, T. (2014). Toll-like receptor signaling pathways. Frontiers in Immunology, 5, 461. https://doi.org/10.3389/fimmu.2014.00461
Kelaini, S., Chan, C., Cornelius, V. A., & Margariti, A. (2021). RNA-binding proteins hold key roles in function, dysfunction, and disease. Biology, 10(5), 366. https://doi.org/10.3390/biology10050366
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016). Recent progress in development of siRNA delivery vehicles for cancer therapy. Advanced Drug Delivery Reviews, 104, 61-77. https://doi.org/10.1016/j.addr.2016.06.011
Krishnamurthy, P., Lambers, E., Verma, S., Thorne, T., Qin, G., Losordo, D. W., & Kishore, R. (2010). Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. The FASEB Journal, 24(7), 2484-2494. https://doi.org/10.1096/fj.09-149815
Kurosu, T., Ohga, N., Hida, Y., Maishi, N., Akiyama, K., Kakuguchi, W., Kuroshima, T., Kondo, M., Akino, T., Totsuka, Y., Shindoh, M., Higashino, F., & Hida, K. (2011). HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. British Journal of Cancer, 104(5), 819-829. https://doi.org/10.1038/bjc.2011.20
Lachiondo-Ortega, S., Delgado, T. C., Baños-Jaime, B., Velázquez-Cruz, A., Díaz-Moreno, I., & Martínez-Chantar, M. L. (2022). Hu antigen R (HuR) protein structure, function and regulation in hepatobiliary tumors. Cancers, 14(11), 2666. https://doi.org/10.3390/cancers14112666
Lal, A., Mazan-Mamczarz, K., Kawai, T., Yang, X., Martindale, J. L., & Gorospe, M. (2004). Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. The EMBO Journal, 23(15), 3092-3102. https://doi.org/10.1038/sj.emboj.7600305
Lejbkowicz, F., Goldberg-Cohen, I., & Levy, A. P. (2005). New horizons for VEGF. Is there a role for nuclear localization? Acta Histochemica, 106(6), 405-411. https://doi.org/10.1016/j.acthis.2004.11.003
Levy, N. S., Chung, S., Furneaux, H., & Levy, A. P. (1998). Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. Journal of Biological Chemistry, 273(11), 6417-6423. https://doi.org/10.1074/jbc.273.11.6417
Lim, S.-J., Lee, S.-H., Joo, S. H., Song, J. Y., & Choi, S. I. (2009). Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer. Cancer Research and Treatment, 41(2), 87-92. https://doi.org/10.4143/crt.2009.41.2.87
Lin, F.-Y., Chen, Y.-H., Lin, Y.-W., Tsai, J.-S., Chen, J.-W., Wang, H.-J., Chen, Y.-L., Li, C.-Y., & Lin, S.-J. (2006).The role of human antigen R, an RNA-binding protein, in mediating the stabilization of toll-like receptor 4 mRNA induced by endotoxin. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(12), 2622-2629. https://doi.org/10.1161/01.ATV.0000246779.78003.cf
Linker, K., Pautz, A., Fechir, M., Hubrich, T., Greeve, J., & Kleinert, H. (2005). Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR. Nucleic Acids Research, 33(15), 4813-4827. https://doi.org/10.1093/nar/gki797
Liu, Y.-J., Lee, L.-M., Lai, H.-L., & Chern, Y. (2015). Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Letters, 589(4), 432-439. https://doi.org/10.1016/j.febslet.2014.12.029
Lukong, K. E., Chang, K., Khandjian, E. W., & Richard, S. (2008). RNA-binding proteins in human genetic disease. Trends in Genetics, 24(8), 416-425. https://doi.org/10.1016/j.tig.2008.05.004
Majumder, M., Chakraborty, P., Mohan, S., Mehrotra, S., & Palanisamy, V. (2022). HuR as a molecular target for cancer therapeutics and immune-related disorders. Advanced Drug Delivery Reviews, 188, 114442. https://doi.org/10.1016/j.addr.2022.114442
Mancini, S. J., & Salt, I. P. (2018). Investigating the role of AMPK in inflammation. In D. Neumann, & B. Viollet (Eds.), AMPK: Methods and protocols (pp. 307-319). Springer. https://doi.org/10.1007/978-1-4939-7598-3_20
Mansfield, K. D., & Keene, J. D. (2012). Neuron-specific ELAV/Hu proteins suppress HuR mRNA during neuronal differentiation by alternative polyadenylation. Nucleic Acids Research, 40(6), 2734-2746. https://doi.org/10.1093/nar/gkr1114
Di Marco, S., Mazroui, R., Dallaire, P., Chittur, S., Tenenbaum, S. A., Radzioch, D., Marette, A., & Gallouzi, I.-E. (2005). NF-κB-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Molecular and Cellular Biology, 25(15), 6533-6545. https://doi.org/10.1128/MCB.25.15.6533-6545.2005
Matsui, K., Nishizawa, M., Ozaki, T., Kimura, T., Hashimoto, I., Yamada, M., Kaibori, M., Kamiyama, Y., Ito, S., & Okumura, T. (2008). Natural antisense transcript stabilizes inducible nitric oxide synthase messenger RNA in rat hepatocytes. Hepatology, 47(2), 686-697. https://doi.org/10.1002/hep.22036
Mayr, C. (2019). What are 3′ UTRs doing? Cold Spring Harbor Perspectives in Biology, 11(10), a034728. https://doi.org/10.1101/cshperspect.a034728
Mazan-Mamczarz, K., Galbán, S., de Silanes, I. L., Martindale, J. L., Atasoy, U., Keene, J. D., & Gorospe, M. (2003). RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proceedings of the National Academy of Sciences, 100(14), 8354-8359. https://doi.org/10.1073/pnas.1432104100
Mehta, M., Basalingappa, K., Griffith, J. N., Andrade, D., Babu, A., Amreddy, N., Muralidharan, R., Gorospe, M., Herman, T., Ding, W.-Q., Ramesh, R., & Munshi, A. (2016). HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget, 7(40), 64820-64835. https://doi.org/10.18632/oncotarget.11706
Meisner, N.-C., Hintersteiner, M., Mueller, K., Bauer, R., Seifert, J.-M., Naegeli, H.-U., Ottl, J., Oberer, L., Guenat, C., Moss, S., Harrer, N., Woisetschlaeger, M., Buehler, C., Uhl, V., & Auer, M. (2007). Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nature Chemical Biology, 3(8), 508-515. https://doi.org/10.1038/nchembio.2007.14
Mrena, J., Wiksten, J.-P., Thiel, A., Kokkola, A., Pohjola, L., Lundin, J., Nordling, S., Ristimäki, A., & Haglund, C. (2005). Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clinical Cancer Research, 11(20), 7362-7368. https://doi.org/10.1158/1078-0432.CCR-05-0764
Mukherjee, N., Corcoran, D. L., Nusbaum, J. D., Reid, D. W., Georgiev, S., Hafner, M., Ascano, M., Tuschl, T., Ohler, U., & Keene, J. D. (2011). Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Molecular Cell, 43(3), 327-339. https://doi.org/10.1016/j.molcel.2011.06.007
Müller-McNicoll, M., Rossbach, O., Hui, J., & Medenbach, J. (2019). Auto-regulatory feedback by RNA-binding proteins. Journal of Molecular Cell Biology, 11(10), 930-939. https://doi.org/10.1093/jmcb/mjz043
Muralidharan, R., Mehta, M., Ahmed, R., Roy, S., Xu, L., Aubé, J., Chen, A., Zhao, Y. D., Herman, T., Ramesh, R., & Munshi, A. (2017). HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Scientific Reports, 7, 9694. https://doi.org/10.1038/s41598-017-07787-4
Nutter, C. A., Jaworski, E. A., Verma, S. K., Deshmukh, V., Wang, Q., Botvinnik, O. B., Lozano, M. J., Abass, I. J., Ijaz, T., Brasier, A. R., Garg, N. J., Wehrens, X. H. T., Yeo, G. W., & Kuyumcu-Martinez, M. N. (2016). Dysregulation of RBFOX2 is an early event in cardiac pathogenesis of diabetes. Cell Reports, 15(10), 2200-2213. https://doi.org/10.1016/j.celrep.2016.05.002
Nutter, C. A., & Kuyumcu-Martinez, M. N. (2018). Emerging roles of RNA-binding proteins in diabetes and their therapeutic potential in diabetic complications. WIREs RNA, 9(2), e1459. https://doi.org/10.1002/wrna.1459
Palacios, I. M. (2007). How does an mRNA find its way? Intracellular localisation of transcripts. Seminars in Cell & Developmental Biology, 18(2), 163-170. https://doi.org/10.1016/j.semcdb.2007.01.008
Palazzo, A. F., & Lee, E. S. (2015). Non-coding RNA: What is functional and what is junk? Frontiers in Genetics, 6, 2. https://www.frontiersin.org/articles/10.3389/fgene.2015.00002
Pereira, B., Billaud, M., & Almeida, R. (2017). RNA-binding proteins in cancer: Old players and new actors. Trends in Cancer, 3(7), 506-528. https://doi.org/10.1016/j.trecan.2017.05.003
Piersma, S. J., Bangru, S., Yoon, J., Liu, T. W., Yang, L., Hsieh, C.-S., Plougastel-Douglas, B., Kalsotra, A., & Yokoyama, W. M. (2023). NK cell expansion requires HuR and mediates control of solid tumors and long-term virus infection. Journal of Experimental Medicine, 220(11), e20231154. https://doi.org/10.1084/jem.20231154
Platania, C. B. M., Pittalà, V., Pascale, A., Marchesi, N., Anfuso, C. D., Lupo, G., Cristaldi, M., Olivieri, M., Lazzara, F., Di Paola, L., Drago, F., & Bucolo, C. (2020). Novel indole derivatives targeting HuR-mRNA complex to counteract high glucose damage in retinal endothelial cells. Biochemical Pharmacology, 175, 113908. https://doi.org/10.1016/j.bcp.2020.113908
Pullmann, R., Juhaszova, M., de Silanes, I. L., Kawai, T., Mazan-Mamczarz, K., Halushka, M. K., & Gorospe, M. (2005). Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. Journal of Biological Chemistry, 280(24), 22819-22826. https://doi.org/10.1074/jbc.M501106200
Qin, H., Ni, H., Liu, Y., Yuan, Y., Xi, T., Li, X., & Zheng, L. (2020). RNA-binding proteins in tumor progression. Journal of Hematology & Oncology, 13, 90. https://doi.org/10.1186/s13045-020-00927-w
Raguraman, R., Srivastava, A., Munshi, A., & Ramesh, R. (2021). Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. Advanced Drug Delivery Reviews, 178, 113918. https://doi.org/10.1016/j.addr.2021.113918
Schneider-Lunitz, V., Ruiz-Orera, J., Hubner, N., & van Heesch, S. (2021). Multifunctional RNA-binding proteins influence mRNA abundance and translational efficiency of distinct sets of target genes. PLoS Computational Biology, 17(12), e1009658. https://doi.org/10.1371/journal.pcbi.1009658
Schultz, C. W., Preet, R., Dhir, T., Dixon, D. A., & Brody, J. R. (2020). Understanding and targeting the disease-related RNA binding protein human antigen R (HuR). Wiley Interdisciplinary Reviews: RNA, 11(3), e1581. https://doi.org/10.1002/wrna.1581
Shang, J., Wan, Q., Wang, X., Duan, Y., Wang, Z., Wei, X., Zhang, Y., Wang, H., Wang, R., & Yi, F. (2015). Identification of NOD2 as a novel target of RNA-binding protein HuR: Evidence from NADPH oxidase-mediated HuR signaling in diabetic nephropathy. Free Radical Biology and Medicine, 79, 217-227. https://doi.org/10.1016/j.freeradbiomed.2014.12.013
Shi, Q., Lee, D.-Y., Féliers, D., Abboud, H. E., Bhat, M. A., & Gorin, Y. (2020). Interplay between RNA-binding protein HuR and Nox4 as a novel therapeutic target in diabetic kidney disease. Molecular Metabolism, 36, 100968. https://doi.org/10.1016/j.molmet.2020.02.011
Shin, J.-S., Choi, H.-E., Seo, S., Choi, J.-H., Baek, N.-I., & Lee, K.-T. (2016). Berberine decreased inducible nitric oxide synthase mRNA stability through negative regulation of human antigen R in lipopolysaccharide-induced macrophages. Journal of Pharmacology and Experimental Therapeutics, 358(1), 3-13. https://doi.org/10.1124/jpet.115.231043
Si, R., Cabrera, J. T. O., Tsuji-Hosokawa, A., Guo, R., Watanabe, M., Gao, L., Lee, Y. S., Moon, J.-S., Scott, B. T., Wang, J., Ashton, A. W., Rao, J. N., Wang, J.-Y., Yuan, J. X.-J., & Makino, A. (2021). HuR/Cx40 downregulation causes coronary microvascular dysfunction in type 2 diabetes. JCI Insight, 6(21), e147982. https://doi.org/10.1172/jci.insight.147982
Simon, L. S. (1999). Role and regulation of cyclooxygenase-2 during inflammation. The American Journal of Medicine, 106(5, Suppl. 2), 37S-42S. https://doi.org/10.1016/S0002-9343(99)00115-1
Slone, S., Anthony, S. R., Wu, X., Benoit, J. B., Aube, J., Xu, L., & Tranter, M. (2016). Activation of HuR downstream of p38 MAPK promotes cardiomyocyte hypertrophy. Cellular Signalling, 28(11), 1735-1741. https://doi.org/10.1016/j.cellsig.2016.08.005
Srikantan, S. (2012). HuR function in disease. Frontiers in Bioscience, 17, 189-205.
Stoppoloni, D., Cardillo, I., Verdina, A., Vincenzi, B., Menegozzo, S., Santini, M., Sacchi, A., Baldi, A., & Galati, R. (2008). Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: Association with cyclooxygenase-2 and prognosis. Cancer, 113(10), 2761-2769. https://doi.org/10.1002/cncr.23904
Sumida, K., Han, Z., Chiu, C.-Y., Mims, T. S., Bajwa, A., Demmer, R. T., Datta, S., Kovesdy, C. P., & Pierre, J. F. (2022). Circulating microbiota in cardiometabolic disease. Frontiers in Cellular and Infection Microbiology, 12, 892232. https://doi.org/10.3389/fcimb.2022.892232
Supe, S., Upadhya, A., Tripathi, S., Dighe, V., & Singh, K. (2023). Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy. Drug Delivery and Translational Research, 13, 1675-1698. https://doi.org/10.1007/s13346-022-01281-9
Suzuki, E., Tsutsumi, A., Sugihara, M., Mamura, M., Goto, D., Matsumoto, I., Ito, S., Ikeda, K., Ochiai, N., Sato, Y., & Sumida, T. (2006). Expression of TNF-alpha, tristetraprolin, T-cell intracellular antigen-1 and Hu antigen R genes in synovium of patients with rheumatoid arthritis. International Journal of Molecular Medicine, 18(2), 273-278.
Wang, J., Guo, Y., Chu, H., Guan, Y., Bi, J., & Wang, B. (2013). Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. International Journal of Molecular Sciences, 14(5), 10015-10041. https://doi.org/10.3390/ijms140510015
Wang, J., Hjelmeland, A. B., Nabors, L. B., & King, P. H. (2019). Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. Cancer Biology & Therapy, 20(7), 979-988. https://doi.org/10.1080/15384047.2019.1591673
Wang, J., Zhao, W., Guo, Y., Zhang, B., Xie, Q., Xiang, D., Gao, J., Wang, B., & Chen, Z. (2009). The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology, 76(6), 420-429. https://doi.org/10.1159/000216837
Wang, W., Caldwell, M. C., Lin, S., Furneaux, H., & Gorospe, M. (2000). HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. The EMBO Journal, 19(10), 2340-2350. https://doi.org/10.1093/emboj/19.10.2340
Wang, W., Fan, J., Yang, X., Fürer-Galban, S., Lopez de Silanes, I., von Kobbe, C., Guo, J., Georas, S. N., Foufelle, F., Hardie, D. G., Carling, D., & Gorospe, M. (2002). AMP-activated kinase regulates cytoplasmic HuR. Molecular and Cellular Biology, 22(10), 3425-3436. https://doi.org/10.1128/MCB.22.10.3425-3436.2002
Wang, W., Yang, X., Kawai, T., de Silanes, I. L., Mazan-Mamczarz, K., Chen, P., Chook, Y. M., Quensel, C., Köhler, M., & Gorospe, M. (2004). AMP-activated protein kinase-regulated phosphorylation and acetylation of importin α1. Journal of Biological Chemistry, 279(46), 48376-48388. https://doi.org/10.1074/jbc.M409014200
Xue, Y. C., Ng, C. S., Xiang, P., Liu, H., Zhang, K., Mohamud, Y., & Luo, H. (2020). Dysregulation of RNA-binding proteins in amyotrophic lateral sclerosis. Frontiers in Molecular Neuroscience, 13, 78. https://doi.org/10.3389/fnmol.2020.00078
Yang, C., Eleftheriadou, M., Kelaini, S., Morrison, T., González, M. V., Caines, R., Edwards, N., Yacoub, A., Edgar, K., Moez, A., Ivetic, A., Zampetaki, A., Zeng, L., Wilkinson, F. L., Lois, N., Stitt, A. W., Grieve, D. J., & Margariti, A. (2020). Targeting QKI-7 in vivo restores endothelial cell function in diabetes. Nature Communications, 11, 3812. https://doi.org/10.1038/s41467-020-17468-y
Yang, X., Han, B., He, Z., Zhang, Y., Lin, K., Su, H., Hosseini, D. K., Sun, H., Yang, M., & Chen, X. (2021). RNA-binding proteins CLK1 and POP7 as biomarkers for diagnosis and prognosis of esophageal squamous cell carcinoma. Frontiers in Cell and Developmental Biology, 9, 715027. https://www.frontiersin.org/articles/10.3389/fcell.2021.715027
Yu, C., Xin, W., Zhen, J., Liu, Y., Javed, A., Wang, R., & Wan, Q. (2015). Human antigen R mediated post-transcriptional regulation of epithelial-mesenchymal transition related genes in diabetic nephropathy. Journal of Diabetes, 7(4), 562-572. https://doi.org/10.1111/1753-0407.12220
Zainol, M. I. B., Kawasaki, T., Monwan, W., Murase, M., Sueyoshi, T., & Kawai, T. (2019). Innate immune responses through toll-like receptor 3 require human-antigen-R-mediated Atp6v0d2 mRNA stabilization. Scientific Reports, 9(1), 20406. https://doi.org/10.1038/s41598-019-56914-w
Zamora, R., Vodovotz, Y., & Billiar, T. R. (2000). Inducible nitric oxide synthase and inflammatory diseases. Molecular Medicine, 6(5), 347-373. https://doi.org/10.1007/BF03401781
Zhou, H., Jarujaron, S., Gurley, E. C., Chen, L., Ding, H., Studer, E., Pandak, W. M., Hu, W., Zou, T., Wang, J.-Y., & Hylemon, P. B. (2007). HIV protease inhibitors increase TNF-α and IL-6 expression in macrophages: Involvement of the RNA-binding protein HuR. Atherosclerosis, 195(1), e134-e143. https://doi.org/10.1016/j.atherosclerosis.2007.04.008